BigHat Biosciences
BigHat Biosciences is a biotechnology company that pairs machine learning with a high-throughput, fully integrated wet lab to design next-generation antibody-based therapeutics. Its platform closes the loop between in-silico antibody design and in-house synthesis and characterization, generating proprietary experimental data that trains its models and speeds the discovery of biologics with improved developability. The company has publicly discussed its Reccy antibody design studio (RADS) and has entered machine-learning-enabled biologics collaborations with Eli Lilly (including Lilly TuneLab), Johnson & Johnson, and Lonza/Synaffix. BigHat is a private, venture-backed company (8VC, a16z) and maintains a public GitHub organization of open-source computational-biology tooling. It does not currently publish a public developer API.
BigHat Biosciences is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Antibody Design, Machine Learning, and Drug Discovery.
BigHat Biosciences’ developer surface includes engineering blog and 3 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Build 1
SDKs, sample code, and the tooling you integrate with
Access & Security 1
Authentication, authorization, and security posture
Company 2
The organization behind the API